346 related articles for article (PubMed ID: 20231536)
1. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
[TBL] [Abstract][Full Text] [Related]
2. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
Böhm M; Baumhäkel M; Probstfield JL; Schmieder R; Yusuf S; Zhao F; Koon T;
Am Heart J; 2007 Jul; 154(1):94-101. PubMed ID: 17584560
[TBL] [Abstract][Full Text] [Related]
3. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
4. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
6. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
[TBL] [Abstract][Full Text] [Related]
10. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
Redon J; Mancia G; Sleight P; Schumacher H; Gao P; Pogue J; Fagard R; Verdecchia P; Weber M; Böhm M; Williams B; Yusoff K; Teo K; Yusuf S;
J Am Coll Cardiol; 2012 Jan; 59(1):74-83. PubMed ID: 22192672
[TBL] [Abstract][Full Text] [Related]
12. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Unger T
Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.
Anderson C
J Int Med Res; 2005; 33 Suppl 1():50A-57A. PubMed ID: 16222900
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
[TBL] [Abstract][Full Text] [Related]
15. The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.
Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL
Clin Res Cardiol; 2009 Jul; 98(7):421-33. PubMed ID: 19347385
[TBL] [Abstract][Full Text] [Related]
16. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Yusuf S
Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
[TBL] [Abstract][Full Text] [Related]
17. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
Diener HC
J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
[TBL] [Abstract][Full Text] [Related]
18. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
20. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.
Held C; Gerstein HC; Yusuf S; Zhao F; Hilbrich L; Anderson C; Sleight P; Teo K;
Circulation; 2007 Mar; 115(11):1371-5. PubMed ID: 17339550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
